BofA notes that Dr. Martin Makary, the man who President-elect Donald Trump nominated to lead the Food and Drug Administration as its commissioner, is the Chief Medical Officer for Sesame, a telehealth company that sells compounded semaglutide. The ability for Hims & Hers and peers like Sesame to sell compounded GLP-1s will be decided by the FDA and having a leader of the agency that currently works for a company that operates as a GLP-1 compounder is “at a minimum” a positive incremental development for the future of the broader compounded GLP-1 opportunity, the analyst tells investors. While the firm maintains its Underperform rating on Hims & Hers given negative competitive developments, it acknowledges “the upside risk around GLP-1s.”
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on HIMS:
- Hunterbrook goes long Hims & Hers after short position in June
- Hims & Hers jumps after Trump nominates Dr. Marty Makary for FDA
- HIMS Stock Surges after Court Case with Eli Lilly Gets Put on Hold
- Hims & Hers Health Expands Board with New Appointment
- FDA tirzepatide status report ‘moderately positive’ for Hims & Hers, says Citi
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
